Live from the NIH registry
Studies recruiting near Spartanburg right now
Top 25 of 357 recruiting studies, sorted by proximity — each links to its official registry page
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Advanced Solid Tumors
Phase 1, Phase 2
Interventional 83 participants sought
Prisma Health — Greenville, South Carolina (27.3 mi)
· Sponsor: Jiangsu HengRui Medicine Co., Ltd.
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
BI-LO Charities Children's Cancer Center — Greenville, South Carolina (27.3 mi)
· Sponsor: National Cancer Institute (NCI)
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Amyloidosis, Amyloid Cardiomyopathy
Phase 3
Interventional 587 participants sought
Prisma Health Cancer Institute — Greenville, South Carolina (27.3 mi)
· Sponsor: Eidos Therapeutics, a BridgeBio company
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
Intracerebral Hemorrhage
Phase 3
Interventional 350 participants sought
Prisma Health Greenville Memorial Hospital — Greenville, South Carolina (27.3 mi)
· Sponsor: Joseph Broderick, MD
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Spartanburg Medical Center — Spartanburg, South Carolina (0.5 mi)
· Sponsor: SWOG Cancer Research Network
Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure
Heart Failure
N/A
Interventional 1,200 participants sought
Prisma Health — Greenville, South Carolina (27.3 mi)
· Sponsor: Analog Device, Inc.
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
Bacterial Conjunctivitis
Phase 3
Interventional 400 participants sought
Baxis Site 33 — Greenville, South Carolina (27.3 mi)
· Sponsor: Baxis Pharmaceuticals, Inc.
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Actinic Keratosis
Phase 3
Interventional 160 participants sought
Palmetto Clinical Trial Services, LLC — Greenville, South Carolina (27.3 mi)
· Sponsor: Sun Pharmaceutical Industries, Inc.
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Phase 1, Phase 2
Interventional 160 participants sought
Bon Secours St. Francis Cancer Center — Greenville, South Carolina (27.3 mi)
· Sponsor: Sellas Life Sciences Group
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina (7.8 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Advanced Solid Tumors
Phase 1
Interventional 798 participants sought
Prisma Health-Upstate Cancer Institute — Greenville, South Carolina (27.3 mi)
· Sponsor: Astellas Pharma Global Development, Inc.
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Malignant Glioma
Phase 1, Phase 2
Interventional 132 participants sought
BI-LO Charities Children's Cancer Center — Greenville, South Carolina (27.3 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina (7.8 mi)
· Sponsor: SWOG Cancer Research Network
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Systemic Lupus Erythematosus
Phase 3
Interventional 100 participants sought
Research Site — Greenville, South Carolina (27.3 mi)
· Sponsor: AstraZeneca
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Healthy
Phase 3
Interventional 6,000 participants sought
Tribe Clinical Research, LLC- Greer — Greer, South Carolina (17.1 mi)
· Sponsor: Pfizer
The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation
Supratentorial Hemorrhage
N/A
Observational 500 participants sought
Prisma Health - Upstate — Greenville, South Carolina (27.3 mi)
· Sponsor: Integra LifeSciences Corporation
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina (7.8 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
N/A
Interventional 600 participants sought
Prisma Health Cancer Institute - Butternut — Greenville, South Carolina (27.3 mi)
· Sponsor: NRG Oncology
Pounce™ Thrombectomy System Retrospective Registry
Peripheral Arterial Disease, Acute Limb Ischemia
N/A
Observational 500 participants sought
Prisma Health Upstate — Greenville, South Carolina (27.3 mi)
· Sponsor: SurModics, Inc.
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
Phase 2
Interventional 284 participants sought
Velocity Clinical Research - Spartanburg - PPDS — Spartanburg, South Carolina (0.5 mi)
· Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Phase 2
Interventional 189 participants sought
Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina (7.8 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Ganglioneuroblastoma, Nodular, Neuroblastoma
Phase 3
Interventional 478 participants sought
BI-LO Charities Children's Cancer Center — Greenville, South Carolina (27.3 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8
Phase 3
Interventional 474 participants sought
Spartanburg Medical Center — Spartanburg, South Carolina (0.5 mi)
· Sponsor: NRG Oncology
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Muscle-invasive Urothelial Carcinoma
Phase 2
Interventional 62 participants sought
Bon Secours - St. Francis Hospital — Greenville, South Carolina (27.3 mi)
· Sponsor: Hoffmann-La Roche
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
Advanced Solid Tumor
Phase 1, Phase 2
Interventional 387 participants sought
Prisma Health — Greenville, South Carolina (27.3 mi)
· Sponsor: OncoC4, Inc.